Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...

- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 - - Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 - ...

- Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - - Combined company Senti...

SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced the appointment of Kanya Rajangam, MD, PhD, as...

- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business...

- SENTI-202 oral presentation details systematic optimization of Logic Gating Gene Circuit technology in allogeneic CAR-NK cells to more precisely target tumor cells in acute myeloid leukemia, while...